Please ensure Javascript is enabled for purposes of website accessibility

The Biggest Loser With Johnson & Johnson's COVID Vaccine Manufacturing Woes

By Keith Speights and Brian Orelli, PhD - May 6, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's obvious.

Although Johnson & Johnson's (JNJ -1.10%) COVID-19 vaccine is no longer on pause, the healthcare giant still faces some major production challenges. In this Motley Fool Live video recorded on April 21, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the biggest loser with J&J's COVID-19 vaccine manufacturing woes.

Keith Speights: We've had news already about the Baltimore facility that was manufacturing Johnson & Johnson's COVID-19 vaccine being shut down while an FDA inspection was under way. Well, reports surfaced today that the FDA has now completed that inspection, and it wasn't pretty, they had some real issues with this facility. The facility remains closed for now.

This is obviously bad news for Johnson & Johnson because the vaccine is not being manufactured at this facility, now. Brian, who would you say is the biggest loser with this fiasco?

Brian Orelli: I mean, it's obviously Emergent BioSolutions (EBS 2.04%) because it's their facility. They're certainly just as big of a loser as Johnson & Johnson, probably more so because in addition to not generating revenue from making Johnson & Johnson's vaccine while it's been shut down. They are also not generating revenue from AstraZeneca's vaccine.

They were making them together and that was what caused the reported contamination. Then the government stepped in and said, you know, just make Johnson & Johnson's only here, so AstraZeneca got kicked out and then you know closing down the plant also, is a stain on Emergents' reputation and Emergent has gone from the pandemic darling to the ugly duckling.

Speights: Yeah, and I saw reports from, I guess it was yesterday. It's getting even worse for Emergent BioSolutions. Now there's a congressional panel, that's investigating whether or not the company was improperly awarded the federal contract of over $600 million. I think there's a house committee wanting to call Emergent's CEO to testify. It's never good when your CEO is called to testify before a congressional committee.

Orelli: No that's never. 

Speights: Never. It's never a good thing. Okay. Yeah, Emergent BioSolutions just has a huge black eye from this. Obviously, it's impacting Johnson and Johnson as well, but not nearly to the extent. We'll continue to watch the story for sure to see what happens.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$30.50 (2.04%) $0.61
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.30 (-1.10%) $-1.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.